222 related articles for article (PubMed ID: 27531973)
1. Adeno Associated Viral Vector Delivered RNAi for Gene Therapy of SOD1 Amyotrophic Lateral Sclerosis.
Stoica L; Sena-Esteves M
Front Mol Neurosci; 2016; 9():56. PubMed ID: 27531973
[TBL] [Abstract][Full Text] [Related]
2. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
[TBL] [Abstract][Full Text] [Related]
3. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
[TBL] [Abstract][Full Text] [Related]
4. GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.
Li K; Hala TJ; Seetharam S; Poulsen DJ; Wright MC; Lepore AC
Neurobiol Dis; 2015 Jun; 78():12-23. PubMed ID: 25818008
[TBL] [Abstract][Full Text] [Related]
5. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques.
Borel F; Gernoux G; Sun H; Stock R; Blackwood M; Brown RH; Mueller C
Sci Transl Med; 2018 Oct; 10(465):. PubMed ID: 30381409
[TBL] [Abstract][Full Text] [Related]
6. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
[TBL] [Abstract][Full Text] [Related]
7. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.
Leyton-Jaimes MF; Kahn J; Israelson A
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14755-14760. PubMed ID: 31262807
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.
Borel F; Gernoux G; Cardozo B; Metterville JP; Toro Cabrera GC; Song L; Su Q; Gao GP; Elmallah MK; Brown RH; Mueller C
Hum Gene Ther; 2016 Jan; 27(1):19-31. PubMed ID: 26710998
[TBL] [Abstract][Full Text] [Related]
9. Silencing strategies for therapy of SOD1-mediated ALS.
van Zundert B; Brown RH
Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
[TBL] [Abstract][Full Text] [Related]
10. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice.
Towne C; Raoul C; Schneider BL; Aebischer P
Mol Ther; 2008 Jun; 16(6):1018-25. PubMed ID: 18414477
[TBL] [Abstract][Full Text] [Related]
11. Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Tokuda E; Furukawa Y
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136532
[TBL] [Abstract][Full Text] [Related]
12. Perspective on SOD1 mediated toxicity in Amyotrophic Lateral Sclerosis.
Sangwan S; Eisenberg DS
Postepy Biochem; 2016; 62(3):362-369. PubMed ID: 28132491
[TBL] [Abstract][Full Text] [Related]
13. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.
Maxwell MM; Pasinelli P; Kazantsev AG; Brown RH
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3178-83. PubMed ID: 14981234
[TBL] [Abstract][Full Text] [Related]
14. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.
Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC
Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261
[TBL] [Abstract][Full Text] [Related]
15. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Jeon GS; Shim YM; Lee DY; Kim JS; Kang M; Ahn SH; Shin JY; Geum D; Hong YH; Sung JJ
Mol Neurobiol; 2019 Mar; 56(3):2007-2021. PubMed ID: 29982983
[TBL] [Abstract][Full Text] [Related]
16. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation.
Shibata N
Neuropathology; 2001 Mar; 21(1):82-92. PubMed ID: 11304046
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.
Miller TM; Kim SH; Yamanaka K; Hester M; Umapathi P; Arnson H; Rizo L; Mendell JR; Gage FH; Cleveland DW; Kaspar BK
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19546-51. PubMed ID: 17164329
[TBL] [Abstract][Full Text] [Related]
18. Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS.
Leyton-Jaimes MF; Benaim C; Abu-Hamad S; Kahn J; Guetta A; Bucala R; Israelson A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):10198-203. PubMed ID: 27551074
[TBL] [Abstract][Full Text] [Related]
19. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.
Kaur SJ; McKeown SR; Rashid S
Gene; 2016 Feb; 577(2):109-18. PubMed ID: 26657039
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors.
Merjane J; Chung R; Patani R; Lisowski L
Med Res Rev; 2023 Jul; 43(4):829-854. PubMed ID: 36786126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
